Lupin Settles Clarinex Patent Lawsuit

Lupin Ltd. has reported to settle all patent infringement lawsuits with Schering-Plough Corp. and Sepracor, Inc. relating anti-allergic drug Clarinex tablets, generically known as desloratadine. Under the terms of the settlement, Lupin will be licensed Clarinex OB listed patents and will be able to commercialize its generic Clarinex tablets on July 01, 2012 or earlier in certain circumstances. Earlier in November 2007, Sepracor and University of Massachusetts filed an infringement lawsuit against Lupin for alleged infringement of the US Patent Nos. 7,214,683 (the ‘683 patent) and 7,214,684 (the ‘684 patent).